ecancermedicalscience

Review

Efficacy of pembrolizumab and oncolytic viral therapy in stage III esophageal cancer: a narrative review

21 Jul 2026
Rajsinh Bhosale, Lamiya Pirzada, Safiyyah Khan, Aqsa Zainab, Shravya Subashini Sivaramakrishnan, Areeba Mariam Mehmood, Pawan Sapkota Upadhya

Pembrolizumab and oncolytic viral therapy represent promising therapeutic strategies for improving outcomes in stage III esophageal cancer. This narrative review evaluates current clinical evidence regarding their efficacy and potential role in contemporary treatment paradigms. A comprehensive literature search was conducted using PubMed, Google Scholar and Web of Science to identify relevant studies published between January 2010 and December 2024. Emerging evidence suggests that pembrolizumab combined with chemotherapy demonstrates encouraging pathological response rates, particularly in esophageal squamous cell carcinoma. Oncolytic viral therapy has shown potential in enhancing tumour immunogenicity and improving local tumour control; however, clinical evidence remains limited. Most available data are derived from early-phase and non-randomised studies, underscoring the need for large randomised controlled trials.

Related Articles

Nikhil Bathija, Rohit Mahajan, Anil Kumar Goel, Siva Ranjani, Mounika Sirimalla, Gourav Kaushal, Sapna Marcus, Shilpa Jain, Madhur Verma, Deep Shikha, Korukonda Vinod Kumar, Jyoti Sharma
Pavan Raju Kola, Amith Paruchuri, Nimisha Preman, Hemavathi Baskarane, Vishakha Hooda, Aparna Sharma, Ishaan Gupta, Saran Kumar, Shilpi Minocha, Pranay Tanwar, Mohit Kumar Divakar, Atul Batra
Jaden Paltoo, Danusha Vinoraj, Elizaveta Klekovkina, Alyssa Tilly, John Bosco, John Lule, Akosua Agyemang, Maria Chikasema, Selena Kleber, Mary Goombs, Iddi Matovu, Craig Sinclair, Wendy G. Lichtenthal, Lesley Chalklin, Eve Namisango, Gary Rodin